EcoDrugPlus

Transforming Growth Factor, Beta Receptor 1 B

Ensembl ID : ENSGACG00000000970
Gene Symbol: TGFBR1B
1 Cross references
205 Possible Orthologues:

Transient Receptor Potential Cation Channel, Subfamily A, Member 1b

Ensembl ID : ENSGACG00000002794
Gene Symbol: TRPA1B
1 Cross references
201 Possible Orthologues:

Tryptophan Hydroxylase 1 (Tryptophan 5-Monooxygenase) A

Ensembl ID : ENSGACG00000005752
Gene Symbol: TPH1A
1 Cross references
202 Possible Orthologues:

Tryptophan Hydroxylase 1b

Ensembl ID : ENSGACG00000012591
Gene Symbol: TPH1B
1 Cross references
177 Possible Orthologues:

Tubulin Alpha 4a

Ensembl ID : ENSGACG00000014965
Gene Symbol: TUBA4A
1 Cross references
144 Possible Orthologues:

Tubulin, Alpha 8 Like 2

Ensembl ID : ENSGACG00000006424
Gene Symbol: TUBA8L2
2 Cross references
158 Possible Orthologues:

Tubulin, Beta 1 Class Vi

Ensembl ID : ENSGACG00000006306
Gene Symbol: TUBB1
1 Cross references
184 Possible Orthologues:

Tubulin, Beta 2a Class Iia

Ensembl ID : ENSGACG00000013114
Gene Symbol: TUBB2
1 Cross references
301 Possible Orthologues:

Tubulin, Beta 5

Ensembl ID : ENSGACG00000009635
Gene Symbol: TUBB5
1 Cross references
255 Possible Orthologues:

Tubulin, Beta 6 Class V

Ensembl ID : ENSGACG00000002049
Gene Symbol: TUBB6
1 Cross references
141 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSGACG00000020587
Gene Symbol: TYR
2 Cross references
196 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSGACG00000007960
Gene Symbol: TYR
1 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).